Tapinarof Cream Indications
Tapinarof (Vtama) cream 1% is FDA-approved for two indications: topical treatment of plaque psoriasis in adults, and topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. 1
FDA-Approved Uses
Plaque Psoriasis
- Approved for adults only with plaque psoriasis 1
- Applied once daily as a thin layer to affected areas 1
- Initial FDA approval was in May 2022 2
Atopic Dermatitis
- Approved for adults and children ≥2 years of age 1
- Most recent FDA approval expansion in December 2024 3
- Applied once daily to affected areas 1
- Safe even in extensive disease (up to 90% body surface area involvement in pediatric patients as young as 2 years) 4
Clinical Evidence Supporting These Indications
Atopic Dermatitis Efficacy
In Japanese phase 3 trials, tapinarof demonstrated:
- 20.24% of patients achieved clear/almost clear skin at week 8 (vs 2.24% with vehicle, p=0.0007) 5
- 40.3% achieved ≥75% improvement in disease severity at week 8 (vs 4.3% with vehicle) 5
- Efficacy improved over time: 76.6% achieved ≥75% improvement by week 52 5
- Minimal systemic absorption even with extensive application in children (mean Cmax only 2.44 ng/mL) 4
Plaque Psoriasis Efficacy
- Notable for durable remission averaging 130 days beyond treatment discontinuation in phase 3 studies 6
- Particularly effective for facial and intertriginous areas where corticosteroid use is problematic 6
Safety Profile
Common adverse reactions include:
- Plaque psoriasis: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, influenza (≥1% incidence) 1
- Atopic dermatitis: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, abdominal pain (≥1% incidence) 1
- Most adverse events are mild to moderate 5
- Follicular inflammatory reactions can occur but are generally manageable 6
Important Clinical Considerations
Tapinarof is NOT approved for oral, ophthalmic, or intravaginal use 1. The medication represents a non-steroidal alternative that works through aryl hydrocarbon receptor agonism, offering a different mechanism than traditional topical corticosteroids or calcineurin inhibitors.
The drug's remittive effect—maintaining improvement well beyond treatment discontinuation—distinguishes it from many other topical therapies and may reduce the need for continuous daily application in responders 6.